Chemically Defined Protocol for Pancreatic Progenitor Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methodologies for generating pancreatic beta cells from human pluripotent stem cells are inefficient, with conversion efficiencies ranging from 10% to 40%, and often result in heterogeneous cell cultures containing unwanted cell types that impede maturation and function, posing risks such as teratoma formation and variable efficiencies depending on the cell line origin.
Innovation Solution
A chemically defined protocol involving a 10-chemical/factor cocktail (PP-10C) and a 3-step differentiation process using specific signaling pathway regulators to efficiently convert pancreatic progenitors into functional beta cells, with improved assembly of 3D clusters and priming for differentiation, achieving up to 80% efficiency of PDX1+ NKX6.1+ cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If current protocols use various growth factors or small molecules to simulate pancreatic beta cell development, then beta cells can be generated through intermediate states, but the conversion efficiency remains low (10%-40%)
Solution Approach 1:
The differentiation process is divided into distinct stages (definitive endoderm, posterior foregut, pancreatic progenitor, endocrine progenitor) with specific chemical compositions for each stage, allowing precise control over conversion efficiency at each step
Solution Approach 2:
The protocol uses defined chemical compositions with specific concentrations of growth factors and small molecules that are optimized for each differentiation stage, changing parameters systematically to achieve high conversion efficiency
2Quantity of substance
If hPSC-derived beta cell cultures are used, then beta cells can be produced, but the cultures are heterogeneous and contain unwanted cell types that impede maturation and function
Solution Approach 1:
The protocol specifically targets and extracts only the desired beta cell lineage through stage-specific chemical signals, eliminating unwanted cell types by not providing the conditions for their differentiation
Solution Approach 2:
Different chemical compositions are applied to different cell populations at different stages, creating local differentiation conditions that guide only the intended cell lineage while suppressing others
3Manufacturing precision
If purification and re-aggregation of hPSC-derived beta cells is performed, then negative influence is alleviated and beta cell maturation is promoted, but the method is not efficient and increases overall cost
Solution Approach 1:
The protocol performs preliminary purification during the differentiation process itself by using stage-specific chemical signals to guide only desired cell types to mature, eliminating the need for post-differentiation purification steps
4Productivity
If heterogeneous cell cultures are used, then beta cell production can proceed, but there is a risk of teratoma formation after transplantations
Solution Approach 1:
The protocol converts the potential harm of heterogeneous cultures into benefit by using controlled chemical signals to eliminate unwanted cell types, thereby reducing teratoma risk while maintaining high beta cell production
5Stability of the object's composition
If the same protocol is applied to different cell lines, then consistency can be maintained, but efficiency varies highly depending on cell line origin
Solution Approach 1:
The protocol uses defined chemical compositions with specific concentrations and stage-specific formulations that can be adjusted to optimize performance across different cell line origins while maintaining consistent differentiation principles
Data Source
AI summary
Compositions for generating a pancreatic beta-like cell population from a population of undifferentiated cells and methods of use thereof, are provided. The method is an 8 stage process interrupted by a priming step, and it includes; using a chemically defined protocol for the efficient generation of pancreatic progenitors (PPs); improved assembly PPs into 3D clusters; a priming step which uses a chemical/factor cocktail (PP-10C) to maintain 3D-PPs status and enhances their potential to differentiate into β cells ;and a 3-step differentiation protocol using select chemical cocktails that efficiently converts PP-10C-treated 3D-PPs into functional β cells.The disclosed methods result in a population of functional β cells which expresses pancreatic cell markers selected from the group of c-peptide, the transcription factors NKX6.1, PDX1, PAX6, NEUROD1 and are INS+, and which do not express substantial levels Glucagon (GCG).The functional β cells can be used to treat conditions such as diabetes.